Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Neurocrine Biosciences is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences stocks (NBIX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $98.99 – an increase of 2.97% over the previous week. Neurocrine Biosciences employs 1,200 staff and has a trailing 12-month revenue of around $1.5 billion.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Latest market close | $97.05 |
|---|---|
| 52-week range | $75.25 - $129.29 |
| 50-day moving average | $103.46 |
| 200-day moving average | $106.77 |
| Wall St. target price | $126.22 |
| PE ratio | 59.4688 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.60 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $97.05 from 2023-03-24
| 1 week (2023-03-17) | 2.97% |
|---|---|
| 1 month (2023-02-24) | -5.27% |
| 3 months (2022-12-23) | -19.33% |
| 6 months (2022-09-26) | -3.50% |
| 1 year (2022-03-22) | N/A |
|---|---|
| 2 years (2021-03-26) | -1.83% |
| 3 years (2020-03-26) | 4.90% |
| 5 years (2018-03-23) | 19.08% |
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $1.5 billion |
|---|---|
| Operating margin TTM | 16.73% |
| Gross profit TTM | $1 billion |
| Return on assets TTM | 7.01% |
| Return on equity TTM | 10.03% |
| Profit margin | 10.38% |
| Book value | $17.70 |
| Market capitalisation | $9.2 billion |
TTM: trailing 12 months
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $75.25 up to $129.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.4974. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Everything we know about the Neuraxis IPO plus information on how to buy in.
Everything we know about the Brera IPO plus information on how to buy in.
Everything we know about the TXO Energy IPO plus information on how to buy in.
Your guide to how ETFs work and whether this type of investment is right for you.
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
The best stock trading app for beginners is easy to use and offers free trades.
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
